PubMed Health⌕ Search

Biomedical subjects

D S Freestone

Publications and source records attributed to D S Freestone.

At least 37 records · Page 2Linked to original sources
PubMed1979

Vaccination against rubella in Britain: benefits and risks.

The benefits and risks of rubella vaccine differ with the programme of vaccination adopted. Programmes in which vaccine is primarily administered to girls aged 11 to 13 years are slow in achieving effects on the incidence of congenital rubella because of the 10 year delay between vaccination and peak child-bearing. In Britain an increase in the percentage of women rubella antibody seropositive and a fall in the numbers of pregnancies terminated for rubella have occurred following the introduction of vaccination for 13 year old girls in 1970. The majority of women will continue to be protected by the sturdy immunity elicited by natural infection occurring before vaccination. Programmes which vaccinate boys and girls before school entry aim to shield pregnant women from infection and are more rapid in effects. However, in such populations immunity becomes predominantly vaccine induced, while vaccination at an earlier age requires the immunity to be more durable. In general, reactions to rubella vaccine increase with the age of the vaccine. Nevertheless, there are few significant reactions to vaccine and for the individual vaccinee the risks of vaccination are low.

Abortion, Induced↗
PubMed1977

Rubella in Orkney: seroepidemiology and vaccination.

Rubella haemagglutination inhibiting (HAI) antibody titres were determined in 54 seronegative women and 31 naturally immune women after vaccination and revaccination with Wistar RA27/3 strain rubella vaccine administered by the intranasal or subcutaneous routes or revaccination with the Cendehill strain administered subcutaneously. In addition, HAI antibody titres were determined in 46 seronegative schoolgirls after vaccination with the Cendehill strain and revaccination with the RA27/3 strain.All seronegative women vaccinated with the RA27/3 strain developed antibody, peak titres being reached 6 weeks after vaccination. Six months after vaccination with the Cendehill strain, 45 (98%) of the 46 seronegative girls had developed antibody, but 11 (24%) had not reached their peak titre by 6 weeks, suggesting a slower response than that elicited by the RA27/3 strain. Revaccination did not induce significant antibody responses in the seronegative women vaccinated 6 months previously with RA27/3 but 4 naturally immune women developed an eightfold increase in antibody. In 10 (22%) of 46 schoolgirls previously vaccinated with the Cendehill strain a significant rise in antibody followed revaccination with RA27/3. These results provide further evidence of the more rapid antibody responses elicited by the RA27/3 vaccine in comparison with the Cendehill vaccine.An outbreak of natural rubella occurred in 1972 and 97 cases were confirmed serologically. The clinical disease was more common in older school-children and in adults. More males than females were affected in the 11-15 age group, the sex ratio being 18:12; this may be explained by the routine vaccination of girls of this age group as part of the national programme which began in 1970. The significance of the persistence of high HAI antibody titres after natural infection and the effect of the epidemic on the serological status of the population are discussed.

Adolescent↗
PubMed1976

WRL 105 strain (H3N2) live attenuated influenza vaccine: acceptability, reactivity, and antibody response in normal, bronchitic, and geriatric volunteers.

The acceptability, reactivity, and antibody responses of recombinant WRL 105 strain, live, attenuated influenza virus vaccine administered intranasally were studied in seventeen normal adults, and in seventeen bronchitic and twenty-one geriatric volunteers. The effect on peak flow and 1-second forced expiratory volume (F.E.V.1) on the 3rd, 5th, and 7th days after vaccination was measured in the bronchitic and normal groups. Seroconversion occurred in 80% to tht homologous virus, in 40.6% to A/Victoria/3/75, and in 26.5% to A/England/864/75 in subjects with pre-vaccination haemagglutination inhibition titres of less than 1/40. A fourfold or greater increase in homologous anti-neuraminidase antibody was found in 48% of twenty-seven infected subjects when measured by a new elution inhibition technique. The frequency and nature of symptoms were similar in both infected and non-infected groups. No significant changes in F.E.V.1 occurred, but on days 5 and 7 there was a decrease in peak flow measurements in both infected and non-infected groups when assessed as the percentage change of the pre-vaccination value.

Administration, Intranasal↗
PubMed1976

Comparison of antibody responses and reactivity of "Alice" and WRL 105 strain live influenza vaccines.

Groups of 45 adult volunteers were vaccinated intranasally with a single dose of either "Alice" or WRL 105 strain live influenza vaccines. Seroconversion rates against A/Scotland/840/74 were significantly greater following administration of WRL 105 but seroconversion rates against A/England/42/72, A/Port Chalmers/1/73, A/Finland/4/74, A/Victoria/3/75, and A/England/864/75 did not differ significantly between the two vaccines. Poor antibody responses were elicited by both "Alice" and WRL 105 strains against A/Victoria/3/75 and A/England/864/75. No severe reactions followed the administration of either vaccine.

Administration, Intranasal↗
PubMed1976

A clinical trial of WRL 105 strain live attenuated influenza vaccine comparing four methods of intranasal vaccination.

A single intranasal dose of 10(7-0) EID50 recombinant WRL 105 strain live attenuated influenza vaccine was administered intranasally to 193 volunteers either as nose drops or by one of three spray devices which produced sprays of differing physical characteristics. In volunteers with homologous haemagglutinating inhibiting antibody titres of less than or equal to 20 before vaccination, seroconversion rates varied widely from 80% following the administration of drops to 71%, 57% and 28% with the three spray devices. In the week following vaccination 16 (22%) of 74 volunteers who were found to show a fourfold or greater antibody response to took analgesics to control symptoms in comparison with 4 (7%) of 58 volunteers who exhibited no serological response to vaccination (P less than 0-05). However, neither the occurrence of upper respiratory nor systemic symptoms were significantly different in these two groups and the degree of attenuation of the recombinant WRL 105 strain appears to be acceptable for future use.

Adult↗
PubMed1976

WRL 105 strain live attenuated influenza vaccine; comparison of one and two dose schedules.

Haemagglutinating inhibiting antibody (HAI) responses were determined and clinical reactions recorded in 162 adult volunteers who received either 1 or 2 intranasal doses of 10(7-0) EID50 WRL 105 strain live influenza vaccine or placebo. After administration of a single dose of vaccine significant antibody responses were obtained in 69 (70%) of 98 volunteers with initial antibody titres of less than or equal to 1/20. Of the 70 volunteers who received a second dose of vaccine, 62 provided a further post-vaccination sample of serum, and only 3 (4-8%), who had not responded to the first dose of vaccine, produced a significant antibody response. Local, upper respiratory and constitutional symptoms were recorded more frequently after the administration of a first dose of vaccine than after placebo or a second dose of vaccine. The symptoms were of a minor nature except in one volunteer who, after the first dose of vaccine, developed influenzal symptoms followed by bronchitis.

Administration, Intranasal↗
PubMed1976

Natural challenge of subjects vaccinated with WRL 105 strain live influenza vaccine in a residential community.

In the spring of 1975 an outbreak of influenza associated with influenza virus A/Scotland/840/74 virus occurred in a residential college where the previous autumn some students had been immunised with a single intranasal dose of Recombinant WRL 105 (H3N2) (A/Okuda/57xA/Finland/4/74) strain live attenuated infleunza virus vaccine. During the outbreak none of seven students who had been vaccinated suffered from influenza but an influenzal illness did occur in four of eleven who had received placebo nose drops only. Fourfold or greater increases in hemagglutinating inhibiting antibodies between sera collected three weeks after vaccination and those collected three months later following the influenza epidemic were found in one of seven vaccinated and in nine of eleven placebo treated subjects and also in one student who had received neither vaccine nor placebo; a difference in serological response which is statistically significant (p less than 0.01). Thus recombinant WRL 105 live attenuated vaccine was found to have conferred substantial protection against a current wild strain of influenza A virus without causing any appreciable untoward reactions.

Administration, Intranasal↗
PubMed1976

A clinical trial of WRL 105 strain live attenuated influenza vaccine comparing four methods of intranasal vaccination.

A single intranasal dose of 10(7.0)EID50 recombinant WRL 105 strain live attenuated influenza vaccine was administered intranasally to 193 volunteers either as nose drops or by one of three spray devices which produced sprays of differing physical characteristics. In volunteers with homologous hemagglutinating inhibiting antibody titres of less than or equal to 20 before vaccination, seroconversion rates varied widely from 80% following the administration of drops to 71%, 57% and 28% with each of the spray devices. In the week following vaccination 16 (22%) of 74 volunteers who were found to show a fourfold or greater antibody response took analgesics to control symptoms in comparison with 4 (7%) of 58 volunteers who exhibited no serological response to vaccination (p less than 0.05). However, neither of the occurrence of upper respiratory nor systemic symptoms were significantly different in these two groups and the level of attenuation of the recombinant WRL 105 strain appears to be acceptable for future use.

Adult↗
PubMed1976

Clinical trials carried out to assess non-parenteral routes for administration of Wistar RA 27/3 strain live attenuated rubella vaccine.

The problems encountered in obtaining acceptable seroconversion rates following intranasal and buccal administration of Wistar RA 27/3 strain live attenuated rubella vaccine are discussed with reference to vaccination technique, virus dose and other factors. Results from buccal administration of vaccine were not encouraging. However, intranasal vaccination may be acceptable if devices can be developed for the administration of vaccine which give reproducible sero-conversion rates equivalent to those obtained by subcutaneous vaccination.

Administration, Intranasal↗